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Abstract: Group B Streptococcus serotypes Ia and Ib capsular
polysaccharides are key targets for vaccine development. In
spite of their immunospecifity these polysaccharides share
high structural similarity. Both are composed of the same
monosaccharide residues and differ only in the connection
of the Neu5Aca2-3Gal side chain to the GlcNAc unit, which
is a b1-4 linkage in serotype Ia and a b1-3 linkage in sero-
type Ib. The development of efficient regioselective routes
for GlcNAcb1-3[Glcb1-4]Gal synthons is described, which
give access to different group B Streptococcus (GBS) Ia and
Ib repeating unit frameshifts. These glycans were used to
probe the conformation and molecular dynamics of the two
polysaccharides, highlighting the different presentation of
the protruding Neu5Aca2-3Gal moieties on the polysaccha-
ride backbones and a higher flexibility of Ib polymer relative
to Ia, which can impact epitope exposure.
Introduction
Group B Streptococcus (GBS) is a leading cause of pneumonia,
sepsis, meningitis, and death in neonates.[1] It has also been as-
sociated with high rates of invasive diseases in the elderly.[1]
On the basis of variation in polysaccharide composition, the
GBS sialic acid-rich capsular polysaccharides (CPSs) are divided
into ten serotypes (Ia, Ib, and II–IX).[2] GBS CPSs are key viru-
lence factors and considered the prime vaccine candidate to
combat GBS infections.[3] Monovalent conjugate vaccines pre-
pared with GBS type-specific polysaccharides representing the
most frequent disease-causing serotypes (Ia, Ib, II, III, and V), as
well as a trivalent combination (Ia, Ib, III), have been tested in
phase I/II clinical trials[4] with the ultimate goal of developing a
maternal vaccination strategy.[1, 5] Multivalent formulations with
six different serotypes are currently under clinical testing.[6]
GBS serotypes Ia, Ib, and III account for the majority of GBS re-
lated diseases.[7] CPS Ia and Ib are structurally very similar. Both
are composed of the same monosaccharide residues and differ
only in the linkage between the Neu5Aca2-3Gal side chain
and the GlcNAc unit : a b1-4 linkage in type Ia and a b1-3 link-
age in type Ib.[8] This difference is critical in determining the
immunospecificity (Figure 1).[3, 9]
The repeating units of CPS Ia and Ib can be described by
the branched 1, 3 and linear 2, 4 frameshifts depicted in
Figure 1. Intriguingly, the latter pentasaccharides 3 and 4 share
identical monosaccharide composition with milk oligosacchar-
ides, which have recently been proposed to inhibit GBS coloni-
zation.[10] The availability of well-defined GBS CPS glycans is
key to explore interactions with serotype-specific monoclonal
antibodies in order to identify relevant glycoepitopes for eluci-
dating the mechanism of action of the polysaccharide conju-
gates and for the development of synthetic carbohydrate-
based vaccines.[11] The most studied of GBS polysaccharides is
type III. This CPS is known to form a helical structure,[12] and
this feature has an impact on epitope exposure.[13] Our group
has recently synthesized CPSIII oligosaccharides that were used
along with fragments obtained from CPS depolymerization to
map a sialylated structural epitope spanning two repeating
units.[14] Considering that neither chemical nor enzymatic de-
polymerization reactions are available for CPS Ia and Ib, chemi-
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cal synthesis is the only approach to obtain homogeneous oli-
gosaccharides from the CPS.
Although the synthesis of the GBS CPS Ia repeating unit has
been reported,[15] the preparation of the pentasaccharide re-
peating unit of GBS CPS Ib has not been achieved. When ap-
proaching the synthesis of CPS Ia and Ib fragments, we envis-
aged the formation of the disaccharide GlcNAcb1-3Gal motif as
a key step to enable convergent syntheses of a variety of struc-
tures depicted in Figure 1. Typically, installation of the
GlcNAcb1-3Gal disaccharide within more complex glycans has
been achieved with the 4-hydroxyl group of the Gal acceptor
either protected[16, 17] or already engaged in a glycosidic link-
age.[18] Particularly, in the preparation of CPS Ia repeating
units[15] a 4,6-O-benzylidene-protected Gal acceptor was used
for glycosylation with a glucosamine trichloroacetimidate
donor, and subsequent regioselective ring opening before fur-
ther glycosylation of position 4 for the construction of the tri-
saccharide GlcNAcb1-3[Glcb1-4]Gal could take place. There is
need of expeditious procedures for the construction of com-
plex glycans, and regio- and stereoselective reactions distin-
guishing among diverse deprotected hydroxyls are highly de-
sirable to simplify the oligosaccharide assembly.[19] We rea-
soned that regioselective glycosylation of Gal 3-OH would be
the key for accelerating the synthesis of the GlcNAcb1-3Gal
disaccharide and rendering the 4-OH available for further gly-
cosylation without the need of tedious protection/deprotec-
tion sequences.[20]
Herein, we report tactics to achieve regioselective syntheses
of protected GlcNAcb1-3Gal building blocks and the use of
these key synthons in convergent routes towards a series of
fragments from CPS Ia and Ib repeating units with a built-in
aminopropyl linker amenable for future conjugation to carrier
proteins (Figure 1). Furthermore, combination of NMR data
from the synthetic GBS CPS Ia and Ib repeating units in their
branched form 1 and 3, respectively, and molecular dynamics
simulation allowed to shed light on how the variation of a
single sugar connection dramatically affects the conformational
properties of CPS Ia and Ib polysaccharides, and hence exposi-
tion of potential epitopes for antibody recognition.
Results and Discussion
Optimization of regioselective glycosylation of galactose
According to our retrosynthetic design (Figure 1), the target
glycans 1–4 can be obtained through a [2+3] convergent
Figure 1. A) Chemical structure of GBS CPS Ia and Ib. B) Chemical structure of the target fragments from GBS CPS Ia (1 and 2) and CPS Ib (3 and 4). Synthesis
of an unsialylated form of CPS Ia repeating units 5 was also envisaged.
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strategy based on the glycosylation of a suitable trisaccharide
acceptor with a Neu5Aca2-3Gal donor. This approach envisag-
es the challenging stereoselective a sialylation of the upstream
galactose at an early stage of the synthesis.[21] Alternative use
of a Gal donor would enable the synthesis of 5. In this design,
faster and efficient access to a GlcNAcb1-3Gal disaccharide
building block plays a central role to obtain the trisaccharide
acceptor without a temporary protection at position 4 for fur-
ther assembly of GBS CPS Ia fragments. To achieve its regiose-
lective synthesis, we investigated the effect of arming benzyl
and disarming benzoyl groups[22, 23] at position 2 and 6 of the
Gal acceptors in tuning the reactivity of the 3- and 4-OH, re-
spectively, in combination with various protecting and leaving
groups in the glucosamine donors. Despite the expected
higher reactivity of the equatorial 3-OH versus the axial 4-OH,
regioselective glycosylation of position 3 has been shown not
to be trivial.[16] Accordingly, we synthesized a series of glucosa-
mine thioglycoside and trichloroacetimidate donors with the
amine protected by the participating phthalimido (Phth) or tri-
chloroethyl carbamate (Troc) group (experimental procedures
are provided as Supporting Information).
Levulinoyl (Lev) and fluorenylmethyloxycarbonyl (Fmoc)
were selected for temporary protection of either position 3 or
4. Alternatively, a 4,6-O-benzylidene was used to lock the 4-
and 6-hydroxyls to be subjected to regioselective ring opening
delivering the 4-OH at a later stage of the synthesis
(Scheme 1). The prepared donors and acceptors were then
coupled under several glycosylation conditions (Table 1 and
Scheme 1) to optimize the synthesis of the GlcNAcb1-3Gal
building block. The most efficient routes proved to be the
combination of the 2,6-di-O-benzoyl acceptor 11 with both
donor 6 or 7 under N-iodosuccinimide (NIS)/AgOTf-mediated
activation (Table 1, entries 7 and 8), which gave 14 a and 15 a
in yields of 53 and 65 %, respectively, or the imidate 9 and ac-
ceptor 11 (Table 1, entry 9), which enabled the attainment of
14 a in 77 % yield.
Similarly, conditions for the preparation of a GlcNAcb1-3Gal
synthon with a temporary group at its C3’-OH, to allow the en-
suing assembly of GBS CPSIb fragments, were explored
(Table 2 and Scheme 1). The glycosylation of di-O-benzyl ac-
ceptor 10 with donor 16 by using NIS with either TfOH or
AgOTf as co-promoters gave variable mixtures of the b1-3 21 a
Scheme 1. A) Preparation of disaccharide intermediates 12–15 for the synthesis of GBS CPS Ia repeating unit. Promoters and conditions are described in
Table 1. B) Preparation of disaccharide intermediates 21–25 for the synthesis of GBS PSIb repeating unit. Promoters and conditions are described in Table 2.
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and b1-4 21 b disaccharides (Table 2, entries 1 and 2). Again,
the di-O-benzoyl acceptor 11 in the presence of NIS/AgOTf ac-
tivation at @30 8C allowed achieving a yield of 68 % (Table 2,
entry 4), which confirms the improved capacity of the benzoyl
substituents to govern the regioselectivity of the reaction com-
pared with benzyl substituents. These conditions were also ef-
ficient for the GlcNTroc donor 17, which gave 23 a in 65 %
yield (Table 2, entry 6). When the trichloroacetimidate 18 was
used, the yield was increased up to 70 % (Table 2, entry 7),
which corroborates the potential of this type of donor for the
regioselective control of the reaction. Finally, trifluoroacetimi-
date glucosamine 20 bearing a 4,6-O-silylidene protection in
the presence of TMSOTf as promoter afforded the target disac-
charide 25 a in 62 % yield.[24] The slighty higher flexibility or
lower hindering effect of the silylidene relative to that of the
benzylidene group favored the reaction. Overall, these results
indicate that the regioselectivity of the glycosylation benefits
from the decreased nucleophilicity of the axial 4-hydroxyl,
which is intrinsically less reactive than the 3-hydroxyl group, in-
duced by the electron-withdrawing effect of the 2,6-O-benzoyl
as compared with 2,6-di-O-benzyl substituents in the Gal ac-
ceptor.
In addition, mild activation conditions (NIS/AgOTf) for the
thioglycoside donor or the torsional disarming effect of the
benzylidene/silylidene group for the imidate donors appears to
favor the regioselectivity of glycosylation at position 3.
Synthesis of GBS CPS Ia linear and branched repeating units
Having identified the two glycosylation partners giving the
GlcNAcb1-3Gal motif in a regioselective fashion, we elongated
the disaccharide building block to assemble the pentasacchar-
ide repeating unit of GBS CPS Ia. To this end, reactions of glu-
cose donor 26[25] with disaccharide donors 12 a and 14 a were
performed to furnish trisaccharides 27 a and 27 b in 75 and
68 % yield, respectively (Scheme 2). The newly formed glycosi-
dic bond was in b configuration, as expected by the presence
of a participating group.
Despite the deactivating effect of the 6-O-benzoyl ester rela-
tive to that of the 6-O-benzyl ether, the reaction proceeded
with almost identical efficiency (Scheme 2), whereas a perace-
tylated trichloroacetimidate glucose donor with TMSOTf activa-
tion was ineffective for glycosylation of the 4-OH. Considering
the higher regioselectivity and yield achieved in synthesizing
disaccharide 14 a, the resulting trisaccharide 27 b was ad-
vanced in the GBS CPS Ia repeating unit construction and sub-
jected to regioselective opening of the 4,6-O-benzylidene
acetal with BF3·Et2O and Me3N·BH3 to provide the acceptor 28
(70 %).
In order to complete the pentasaccharide construction, the
sialo-galactosyl trifluoroacetimidate donor 29[14a, 26] and thiogly-
coside 30[27] were tested. Of these two disaccharides, 30 can
be prepared with a higher a stereoselectivity, whereas 29 is
easily accessible from a commercial disaccharide precursor.[14a]
Glycosylation of trisaccharide 28 with 29 under TMSOTf acti-
vation gave the protected pentasaccharide 31 in 75 % yield,
and the use of disaccharide 30 in the presence of NIS/TfOH led
to the protected pentasaccharide 32 in a similar yield (73 %).
Compound 30 was deprotected by a four-step procedure,[18]
including 1) saponification of the methyl ester of Neu5Ac with
lithium iodide in pyridine; 2) reaction with ethylenediamine in
ethanol heated to reflux for concomitant removal of the O-ace-
tates and the NPhth protecting group; 3) reacetylation with
acetic anhydride/pyridine to install the acetamide group of the
GlcNAc residue along with acetyl esters ; 4) methanolysis and
final catalytic hydrogenation over Pd/charcoal to provide the
target branched pentasaccharide 1.
Pentasaccharide 32 was first subjected to saponification
with NaOH in THF heated to reflux, followed by amine reacety-
lation with a 2:3 acetic anhydride/methanol mixture.
Hydrogenation over Pd/charcoal afforded the target
branched pentasaccharide 1 equipped with the aminopropyl
linker suitable for conjugation. After purification by size exclu-
sion chromatography, the final compound was obtained in
40 % overall yield from 31 and 45 % overall yield from 32, re-
spectively (Scheme 2).
Table 2. Reaction of glucosamine donors 16–20 with Gal acceptors 10
and 11.
Entry Donor Acceptor Promoter, temperature [8C] Yield [%]
1 16 10 NIS/TfOH, @30 21 a (30)
21 b (<5)
2 16 10 NIS/AgOTf, @30 21 a (38)
21 b (26)
3 16 11 NIS/TfOH, @30 22 a (40)
4 16 11 NIS/AgOTf, @30 22 a (68)
5 17 11 NIS/TfOH, @30 n.d.[a]
6 17 11 NIS/AgOTf, @30 23 a (65)
7 18 11 TMSOTf, @10 23 a (70)
8 19 11 TMSOTf, @10 24 a (50)
9 20 11 TMSOTf, @10 25 a (62)
[a] CH2Cl2 was the solvent in all tested conditions.
Table 1. Reaction of glucosamine donors 6–9 with Gal acceptors 10 and
11.
Entry Donor Acceptor Promoter, temperature [8C] Yield [%]
1 6 10 NIS/TfOH, @30 n.d.[a]
2 6 10 NIS/Ag(OTf), 30 12 a (43)
12 b (26)
3 7 10 NIS/Ag(OTf), @30 13 a (40)
13 b[b] (28)
4 8 10 TMSOTf, @10 12 a (31)
5 9 10 TMSOTf, @10 13 a (45)
6 6 11 NIS/TfOH, @30 n.d.[a]
7 6 11 NIS/Ag(OTf), @30 14 a (53)
8 7 11 NIS/Ag(OTf), @30 15 a (65)
9 8 11 TMSOTf, @10 14 a (77)
10 9 11 TMSOTf, @10 15 a (33)
[a] CH2Cl2 was the solvent in all tested conditions; n.d. = not determined,
product could not be detected; [b] The formation of the b1-4 linkage
was confirmed by acetylation of 13 b. In the 1H NMR spectrum a shift
from 3.32 to 4.69 ppm of the H-3 signal of Gal, appearing as a doublet of
doublets with J2,3 = 10.3 Hz and J3,4 = 2.5 Hz was observed, confirming oc-
currence of glycosylation at position 4.
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Next, we extended the same regioselective approach to the
synthesis of the linear frameshift 2 of the serotype Ia repeating
unit (Scheme 3). In this case, the benzoylated lactose 33 and
the glucosamine donor 8 were chosen as glycosylation part-
ners affording the linear trisaccharide acceptor 34 in 68 % yield
with complete regioselectivity. Following benzylidene opening,
the trisaccharide acceptor 35 was glycosylated with the two
donors 29 and 30. The first glycosylation promoted by TMSOTf
Scheme 2. Assembly of GBS CPS Ia repeating unit. Reagents and conditions: a) TMSOTf, CH2Cl2 dry, @10 8C, (b-) 75 % from 12 a, 68 % (b-) from 14 a ;
b) Me3N·BH3, BF3·Et2O, MeCN, 0 8C, 70 %; c) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 75 %; d) TfOH, NIS, CH2Cl2 dry, @40 8C, (b-) 73 %; e) LiI, Py, 120 8C; H2NCH2CH2NH2,
EtOH, 90 8C; Ac2O, Py; MeONa, MeOH; H2, Pd-C, 40 % (over five steps) ; f) 3 m NaOH, THF, reflux; Ac2O, MeOH; H2, Pd-C, 45 % (over three steps).
Scheme 3. Assembly of linear GBS PS Ia fragments 2. Reagents and conditions: a) TMSOTf, CH2Cl2 dry, @10 8C, (b-) 68 %; b) Me3N·BH3, BF3·Et2O, MeCN, 0 8C,
65 %; c) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 65 %; d) LiI, Py, 120 8C; H2NCH2CH2NH2, EtOH, 90 8C; Ac2O, Py; MeONa, MeOH; H2, Pd-C, 33 % (over five steps) ; e) TFACl,
Cs2CO3, CH2Cl2, 61 %; f) TMSOTf, @20 8C, CH2Cl2, (b-) 72 %; g) PdCl2, MeOH; H2NCH2CH2NH2, EtOH, 90 8C; Ac2O, Py; MeONa, MeOH; H2, Pd-C, 42 % (over five
steps).
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at 0 8C afforded the target linear pentasaccharide 36 in 65 %
yield, with b stereo- and regioselectivity at C-4 of GlcNAc over
the C-4 of Gal. The presence of the free galactose 4-OH
throughout all stages of the synthesis, from trisaccharide 34 to
pentasaccharide 36, was monitored by following the signal of
the Gal H-4, which appeared at 3.97 ppm (d, J = 2.7 Hz) in the
1H NMR and HSQC spectra of all synthetic intermediates. This
confirmed the regioselectivity of the two glycosylations per-
formed. Unexpectedly, reaction of 35 with the tolyl thioglyco-
side 30 under NIS/TfOH activation at @40 8C yielded only
traces of the corresponding pentasaccharide, whereas mainly
decomposition of the glycosyl donor was observed, as re-
vealed by LC-MS analysis. The linear pentasaccharide 36 was
subjected to the five-step deprotection protocol previously de-
scribed for compound 31. The target oligosaccharide 2 was
purified by size exclusion chromatography and obtained in
33 % overall yield (Scheme 3). NMR data of the synthesized
fragments were in excellent agreement with those of the CPS
Ia samples.[8]
From acceptor 35 a desialylated CPS Ia linear fragment for
future mapping studies was also obtained by glycosylation
(72 % yield) with the trifluoroacetimidate 38, prepared from
the known 1-OH compound 37.[18] After global deprotection
tetrasaccharide 5 was obtained in 42 % yield (Scheme 3).
Synthesis of GBS CPS Ib linear and branched repeating unit
Differently than the GBS CPS Ia pentasaccharides, the two Ib
frameshifts 3 and 4 required a glucosamine building block
bearing a temporary protecting group at its C3-OH and the
creation of the Galb1-3GlcNAc linkage, which had a strong
impact on our synthetic design. Initial attempts to prepare the
branched pentasaccharide 3 by using a NPhth-protected trisac-
charide acceptor, similarly as done for the CPS Ia branched
unit, were unsuccessful (Supporting Information, Scheme S9).
The C3-OH of the glucosamine appeared significantly less re-
active than the C4-OH, which is likely due to the presence of
the bulky NPhth group that could hinder the glycosylation re-
action at the C3@OH. We anticipated that its replacement with
a Troc protection would result in a higher nucleophilicity of
the vicinal hydroxyl. Disaccharides 23 a and 25 a, which differ
only in the cyclic protecting group blocking the glucosamine
C4,6@OH groups, were selected to be elongated to the
branched pentasaccharide 3 (Scheme 4). Glycosylation of the
two acceptors with the armed Glc donor 26 under TMSOTf ac-
tivation at 0 8C afforded the trisaccharides 40 and 41 in 63 and
70 % yield, respectively, as b anomers. After Fmoc removal by
treatment with 10 % piperidine in CH2Cl2 (92 %), glycosylation
with the sialogalactoside donor 29 of the two acceptors 42
and 43 was tested.
Reaction of the 4,6-O-benzylidene trisaccharide 42 and 29
with TMSOTf as a promoter failed to afford the target penta-
saccharide, leading to complete recovery of the unreacted ac-
ceptor. In contrast, reaction of acceptor 43, bearing the more
flexible 4,6-O-silylidene ketal, with 29 in the presence of
TMSOTf gave the target pentasaccharide 44 in 80 % yield
(Scheme 4). This result suggests that the glycosylation of 42
was prevented by the steric and torsional constrain of the 4,6-
Scheme 4. Assembly of GBS PSIb pentasaccharide branched unit 3. Reagents and conditions: a) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 63 % for 41, (b-) 70 % or 42 ;
b) piperidine, CH2Cl2 dry, 92 %; c) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 80 %; d) TfOH, NIS, CH2Cl2 dry, @40 8C, (b-) 65 %; e) HF/pyridine, 0 8C; 3 m NaOH, THF, reflux;
Ac2O/MeOH; H2/Pd-C, 40 %.
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O-benzylidene ring. Trisaccharide 43 was also efficiently b-gly-
cosylated with disaccharide donor 30 by NIS/TfOH activation,
affording 45 in 65 % yield (Scheme 4). Despite a slightly lower
yield in this step, the overall efficiency of the synthesis of the
GBS serotype Ib branched repeating unit was superior when
using the thioglycoside 30 with respect to the imidate 29 be-
cause of the better a stereoselectivity of the glycosylation
leading to 30.[26, 27] Pentasaccharides 44 and 45 were then de-
protected by a four-step protocol (Scheme 4): 1) desilylation by
treatment with HF·pyridine, 2) saponification with NaOH in
THF heated to reflux, for concomitant hydrolysis of the acyl
esters, the Troc group, and the 5-N,4-O-oxazolidinone protect-
ing group and Neu5Ac methyl ester, 3) reacetylation of the
amines by a 2:3 acetic anhydride/methanol mixture, 4) hydro-
genation over Pd/charcoal. The target branched pentasacchar-
ide 3 was obtained in 40 % yield.
Finally, we extended our regioselective approach to the syn-
thesis of the linear frameshift 4 of the GBS serotype Ib repeat-
ing unit (Scheme 5). For this purpose, benzoylated lactose ac-
ceptor 33 was glycosylated with the 4,6-O-silylidene glucosa-
mine imidate 20 under TMSOTf activation to give the target
trisaccharide 46 with full b1-3 stereo- and regioselectivity
(55 %). Following Fmoc deprotection with piperidine in CH2Cl2,
the obtained acceptor 47 was b-glycosylated with imidate 29
to attain the linear protected pentasaccharide 48 (66 %). Reac-
tion with thioglycoside 30 in TfOH and NIS reaction conditions
also provided the analogous pentasaccharide 49 (40 %). The
obtained pentasaccharides were deprotected and purified as
described above. NMR spectroscopic data of the synthesized
CPS Ib fragments were in excellent agreement with NMR spec-
troscopic data from samples of the bacterial polysaccharide.[8a]
Conformational analysis
The conformational properties of the CPS Ia and Ib branched
repeating unit pentasaccharides 1 and 3 were studied by a
combination of NMR spectroscopy and modeling tools,[28] and
compared with those of the corresponding polysaccharides. In-
terglycosidic interproton distances for 1 and 3 were estimated
from ROESY spectra. The obtained experimental distances
were compared with those derived from a 200 ns molecular
dynamics (MD) simulation. Table 3 gathers the results for the
CPS Ia pentasaccharide 1. The comparison reflects a good
agreement between the NMR- and the MD-derived distances
for the glycosidic linkages GlcNAcb1-3Gal and Glcb1-4Gal (de-
fined by the interproton distances H1GlcNAc-H3Gal and H1Glc-
H4Gal, respectively). The F/Y population analysis from the MD
simulation showed a single population for F fulfilling the exo-
anomeric effect (exo-syn-F),[29, 30] and two populations around
y for both linkages (Supporting Information, Figure S1).
Scheme 5. Synthetic route to type Ib linear repeating unit. Reagents and conditions: a) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 55 %; b) piperidine, CH2Cl2, 90 %;
c) TMSOTf, CH2Cl2 dry, 0 8C, (b-) 66 %; d) TfOH, NIS, CH2Cl2 dry, @40 8C, (b-) 40 %; e) HF/pyridine; 3 m NaOH, THF, reflux; Ac2O/MeOH; H2/Pd-C, 40 %.
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For the Galb1-4GlcNAc linkage, there is a perfect agreement
for the H1Gal-H4GlcNAc distance with slight discrepancies for
the H1Gal-H6,H6’GlcNAc ones, which is probably due to the
MD bias around the GlcNAc w torsion angle (Supporting Infor-
mation, Figure S2). These data support the existence of a
single population around the exo-syn-F/synY conformation, as
predicted by the MD simulation.
For the Neu5Aca2-3Gal linkage, MD simulations predict
three different populations, 1808/@308, @608/@208, and @608/
@508. The interglycosidic interproton distances for each popu-
lation are gathered in Table 3. There is a remarkable difference
for the H3Gal-H3axNeuNAc distance, being shorter according
to NMR spectroscopy, which indicates that the MD simulation
has a bias for the conformational ensemble towards exo-syn-F
populations. Indeed, according the NOE-derived distance, the
exo-anti-F population should be the major one, representing
around 75 % of the total ensemble. Two representative confor-
mations for the CPS Ia pentasaccharide 1 are shown in the
Supporting Information, differing in the Neu5Aca2-3Gal link-
age (Figure S3). The analysis for the CPS Ib pentasaccharide 3
yielded similar results (Supporting Information, Table S3), al-
though the GlcNAcb1-3Gal linkage could not be fully charac-
terized because of the overlapping between the H1GlcNAc
and H3Gal protons. The linkage between Gal and GlcNAc, now
b1-3 instead of b1-4, populates a minimum around the exo-
syn-F/syn(@)-Y conformation (Supporting Information, Fig-
ure S4). Two representative conformations for the CPS Ib pen-
tasaccharide 3 are shown in the Supporting Information, which
also differ in the orientation around the Neu5Aca2-3Gal F tor-
sion (Supporting Information, Figure S5). A superimposition of
representative 3D structures for the CPS Ia and Ib pentasac-
charides 1 and 3, with the major conformation exo-anti-F
around the Neu5Aca2-3Gal linkage is shown in Figure 2. The
conformational behavior of the polysaccharides was then ana-
lyzed following a similar protocol. A model for the polysaccha-
ride was built with 10 repeating units (50 monosaccharides)
and MD simulations were run for 2.5 ms.
The analysis of the glycosidic linkages was carried out for
the 49 glycosidic bonds, revealing that the behavior for every
glycosidic bond type is reproducible along the polysaccharide
(Figure 3).
These populations are comparable to those of the corre-
sponding pentasaccharide for every glycosidic linkage, and
thus, the resulting interglycosidic interproton distances are
very similar (Supporting Information, Table S1-2). Remarkably,
for both GBS serotype Ia and Ib, the HSQC spectra of the poly-
saccharide and the pentasaccharide were very similar, with the
obvious exception for the Glcb1-4 linked moiety (E), which is
not glycosylated at O4 in the pentasaccharides (Figure 4). The
analysis of the interglycosidic NOE (from NOESY spectra at
20 ms mixing time) was consistent with the MD-derived popu-
lations. The only discrepancies arose again for the Neu5Aca2-
3Gal linkages. Interestingly, for the Ia polysaccharide the NOE-
derived distance for H3axNeu5Ac-H3Gal is 2.4 a, shorter than
that in the pentasaccharide. At the same time, there is a clear
NOE between H3eqNeu5Ac-H3Gal, not observed for the penta-
saccharide. On the contrary, for the Ib polysaccharide the dis-
tance H3axNeu5Ac-H3Gal is longer, 3.3 a, whereas the NOE be-
tween H3eqNeu5Ac-H3Gal does not exist (Figure 5 A, B). At the
same time, the distance H8Neu5Ac-H3Gal is slightly shorter for
the Ib than that for the Ia polysaccharide (Figure 5 C, D). These
data suggest that for the Ia polysaccharide, the major confor-
mation around the Neu5Aca2-3Gal fragment is the exo-anti-F
(ca. 85 %), whereas for the Ib polysaccharide, there is a larger
flexibility, with a major exo-syn-F form (ca. 55 %). The model
structures for the polysaccharides with all Neu5Aca2-3Gal link-
Figure 2. Superimposition of the major conformations for pentasaccharides
1 (lime) and 3 (grey), with the exo-anti-F geometry around the Neu5Aca2-
3Gal linkage.
Figure 3. Glycosidic linkage analysis for GBS Ia (A) and Ib (B) polysaccharides: F/Y plots for representative glycosidic bonds of a 10 repeating unit model
along the 2.5 ms MD simulation.
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ages in exo-anti-F (Ia) and exo-syn-F (Ib) are displayed in
Figure 6, showing different preferential shapes for the two
polysaccharides. The Neu5Aca2-3Gal branches of GBS PSIII
have been shown to be strongly engaged in antibody recogni-
Figure 4. 1H-13C-HSQC spectrum recorded for the pentasaccharide repeating unit of GBS Ia at 600 MHz, 298 K, D2O (A and B) and for GBS CPS Ib at 800 MHz,
318 K, D2O, showing the assignment of the
1H and 13C NMR signals. As expected, the matching is excellent except for some signals of residue E.
Figure 5. The key regions of the NOESY spectra recorded for the GBS CPS Ia (A and C) and GBS CPS Ib (B and D) polysaccharides showing the essential inter-
residue cross peaks.
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tion.[14b] The favored presentation of the different epitopes for
the major conformation is rather different. However, given
their intrinsic flexibility, especially for Ib, both molecules could
be accommodated to interact with the monoclonal binding
pockets without a major entropy penalty.[31]
Conclusions
To have fast access to homogeneous oligosaccharide antigens
from GBS serotypes Ia and Ib and to gain insights into the con-
formational difference among these structurally similar poly-
mers, we developed a highly convergent synthetic strategy
based on the regioselective glycosylation of a galactose C3,4-
diol to obtain GlcNAcb1-3Gal disaccharide building blocks. In-
vestigation of the different reactivities of the C3- and C4-hy-
droxyls allowed us to reduce the number of protective group
manipulations and synthetic steps to the final fragments,
therefore simplifying the overall synthetic design.
Particularly, the use of a 2,6-O-benzoyl galactose diol result-
ed in improved regioselectively relative to that of the 2,6-di-O-
benzyl counterpart. In addition, mild activation conditions
(NIS/AgOTf) for the glucosamine thiol donors or the torsional
disarming effect of the benzylidene group for the trichloroace-
timidate donors appear to favor the glycosylation reaction. The
regioselective glucosamine incorporation was successfully ap-
plied to the synthesis of GBS CPS Ia and Ib branched repeating
units (1 and 2). Their linear frameshifts (3 and 4) and a non-sia-
lylated CPS Ia form (5) were also synthesized to achieve an ad-
ditional regioselective glycosylation of the Gal C3-OH over the
C4-OH residue.
These results support the general applicability of the
method to a variety of medically relevant glycans. Importantly,
the structures synthesized through regioselective glycosylation
appear extendible at the 4-OH position of the Gal residue, thus
potentially enabling the synthesis of longer and more complex
GBS oligosaccharide structures.
Conformation analysis studies of the prepared oligosacchar-
ides by NMR spectroscopy and MD simulations showed the
impact of the GlcNAcb1-3Gal versus GlcNAcb1-4Gal connectivi-
ty in the orientation of the Neu5Aca2-3Gal branching. The
model, established from the single synthetic pentasaccharide
repeating units, was used to study the conformational behav-
ior of the GBS Ia and Ib polysaccharides, showing a different
preferential shape for each polysaccharide with the Neu5Aca2-
3Gal linkages in exo-anti-F for Ia and exo-syn-F for Ib. These
unique structural features are expected to influence antibody
recognition and immunospecificity. Studies are ongoing to
map the relevant glycoepitopes. Moreover, all glycans were de-
signed with a chemical handle for conjugation to carrier pro-
teins for immunological evaluation. Results on structural and
immunogenic studies will be reported in due course.
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